CryoPort Inc. Reports Strong Q2 2026 Performance with First Positive Adjusted EBITDA

CryoPort Inc. (NASDAQ: CYRX) announced its financial results for the second quarter of 2026 and the first half of the year on August 6, 2026. The company, a global provider of integrated temperature‑controlled supply chain solutions for the life sciences, confirmed a steady revenue increase and highlighted a pivotal milestone in its path toward sustainable profitability.

Revenue Growth Across Key Segments

  • Total Q2 revenue rose 8 % year‑over‑year to $49.0 million, surpassing expectations and beating the $48.24 million forecast by $0.76 million.
  • Life Sciences Services generated $27.97 million in the quarter, up 15 % YoY, reflecting a 25 % increase in BioStorage/BioServices revenue.
  • BioLogistics Solutions contributed $22.36 million, growing 13 % YoY.
  • Life Sciences Products maintained a steady revenue level of $21.00 million.

For the first half of 2026, the company recorded $98.8 million in total revenue, reflecting 16 % growth compared with the same period in 2025.

Supporting a Record‑High Clinical Trial Footprint

CryoPort reported that it supported 779 global clinical trials as of June 30, 2026, a record for the company. The Life Sciences Services segment that backs commercial cell‑and‑gene therapies (CGT) grew 26 % YoY to $9.4 million, while revenue from CGT clinical trials increased 12 % YoY to $13.4 million. The company currently supports 22 commercially approved CGT products, underscoring its position at the forefront of the rapidly expanding regenerative medicine market.

Milestone in Profitability

A key highlight of the quarter was CryoPort’s first positive adjusted EBITDA. CEO Jerrell Shelton emphasized that this achievement reflects the effectiveness of the company’s strategic investments and operational initiatives undertaken over the past several years. “Our revenue momentum over the past several periods continued into the second quarter…and achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability,” Shelton said.

The company’s focus on expanding its Global Supply Chain Center Network and launching new products and services is expected to drive further growth, enhance operating efficiency, and elevate profitability.

Earnings Per Share

On a GAAP basis, CryoPort reported an earnings per share (EPS) of ‑$0.20, which aligns with analyst expectations. Although the company remains unprofitable on an EPS basis, the positive adjusted EBITDA indicates progress toward financial turnaround.

Outlook

CryoPort remains committed to executing its strategy, optimizing global operations, and capitalizing on the growing opportunities in the life sciences supply chain market. The company’s expansion initiatives and continued demand for its temperature‑controlled solutions position it well to sustain long‑term growth and improve shareholder value.

This article is based exclusively on publicly available financial data and company statements released on August 6, 2026.